Short answer
Biomarin Pharmaceutical Inc (BMRN) filed an 8-K current report with the SEC on August 31, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). BioMarin grants Ascendis global rights to TransCon CNP, navepegritide, and Yuviwel products.
Biomarin Pharmaceutical Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- BioMarin grants Ascendis global rights to TransCon CNP, navepegritide, and Yuviwel products
- Royalty stream: 20% of U.S. net sales and 18% in the EU, Brazil, and South Korea through May 2030
- Settlement ends all pending patent litigation, with Ascendis barred from challenging BioMarin patents
- License covers achondroplasia, hypochondroplasia, and potential future indications
- Binding term sheet remains effective if definitive agreement is not signed by September 24, 2026
Item 7.01 · Regulation FD Disclosure
- BioMarin announced execution of a Term Sheet, signaling a potentially material transaction or strategic arrangement
- Exhibit 99.1 contains the press release and terms investors need to assess scope, obligations, and financial impact
Item EX-99.1 · Exhibit EX-99.1
- Global patent settlement with Ascendis eliminates pending ITC and international litigation over Yuviwel
- Ascendis royalties to BioMarin: 20% of U.S. net sales retroactive to launch
- 18% royalties on Yuviwel net sales in the EU, Brazil and South Korea through May 2030
- License covers current and potential indications, including achondroplasia and hypochondroplasia
- Financial upside depends on Yuviwel sales and BioMarin’s ability to enforce the agreement
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Biomarin Pharmaceutical Inc 8-K filings
Get the next BMRN 8-K as it lands
Follow BMRN for push alerts, or ask the research agent what this filing means.